DE69739319D1 - Verfahren zur Expression von PDGF oder IGR Proteinen in Hefe - Google Patents

Verfahren zur Expression von PDGF oder IGR Proteinen in Hefe

Info

Publication number
DE69739319D1
DE69739319D1 DE69739319T DE69739319T DE69739319D1 DE 69739319 D1 DE69739319 D1 DE 69739319D1 DE 69739319 T DE69739319 T DE 69739319T DE 69739319 T DE69739319 T DE 69739319T DE 69739319 D1 DE69739319 D1 DE 69739319D1
Authority
DE
Germany
Prior art keywords
proteins
isoforms
pdgf
clipped
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69739319T
Other languages
German (de)
English (en)
Inventor
Patricia Tekamp-Olson
James Merryweather
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Novartis Vaccines and Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines and Diagnostics Inc filed Critical Novartis Vaccines and Diagnostics Inc
Application granted granted Critical
Publication of DE69739319D1 publication Critical patent/DE69739319D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0066—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Materials Engineering (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
DE69739319T 1996-12-13 1997-12-12 Verfahren zur Expression von PDGF oder IGR Proteinen in Hefe Expired - Lifetime DE69739319D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3272096P 1996-12-13 1996-12-13

Publications (1)

Publication Number Publication Date
DE69739319D1 true DE69739319D1 (de) 2009-04-30

Family

ID=21866458

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69739319T Expired - Lifetime DE69739319D1 (de) 1996-12-13 1997-12-12 Verfahren zur Expression von PDGF oder IGR Proteinen in Hefe
DE69738768T Expired - Lifetime DE69738768D1 (de) 1996-12-13 1997-12-12 Analyse und separation von pdgf-proteinen
DE69725881T Expired - Lifetime DE69725881T2 (de) 1996-12-13 1997-12-12 Verfahren zur expression von heterologen proteinen in hefe

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE69738768T Expired - Lifetime DE69738768D1 (de) 1996-12-13 1997-12-12 Analyse und separation von pdgf-proteinen
DE69725881T Expired - Lifetime DE69725881T2 (de) 1996-12-13 1997-12-12 Verfahren zur expression von heterologen proteinen in hefe

Country Status (9)

Country Link
US (10) US6017731A (https=)
EP (4) EP1935901A1 (https=)
JP (4) JP4275741B2 (https=)
AT (3) ATE253120T1 (https=)
AU (2) AU5465498A (https=)
DE (3) DE69739319D1 (https=)
ES (1) ES2306462T3 (https=)
PT (1) PT948538E (https=)
WO (2) WO1998025963A1 (https=)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207842A (en) 1983-04-25 1988-02-12 Chiron Corp Production of human insulin-like growth factor (igf) using cdna
US7883872B2 (en) * 1996-10-10 2011-02-08 Dyadic International (Usa), Inc. Construction of highly efficient cellulase compositions for enzymatic hydrolysis of cellulose
US5811381A (en) * 1996-10-10 1998-09-22 Mark A. Emalfarb Cellulase compositions and methods of use
EP1935901A1 (en) * 1996-12-13 2008-06-25 Novartis Vaccines and Diagnostics, Inc. Analysis and separation of platelet-derived growth factor proteins
KR100618495B1 (ko) * 1998-10-06 2006-08-31 마크 아론 에말파브 섬유상의 진균성 숙주 영역에서의 형질전환 시스템:크리소스포륨속에서
US20040146918A1 (en) * 2000-02-18 2004-07-29 Weiner Michael L. Hybrid nucleic acid assembly
US7166712B2 (en) * 2000-07-12 2007-01-23 Philadelphia, Health And Education Corporation Mammalian MDM2 binding proteins and uses thereof
WO2005011619A2 (en) * 2003-01-31 2005-02-10 Five Prime Therapeutics, Inc. Lung-expressed polypeptides
US7960148B2 (en) 2003-07-02 2011-06-14 Verenium Corporation Glucanases, nucleic acids encoding them and methods for making and using them
DE10342794A1 (de) * 2003-09-16 2005-04-21 Basf Ag Sekretion von Proteinen aus Hefen
WO2005055944A2 (en) 2003-12-05 2005-06-23 Cincinnati Children's Hospital Medical Center Oligosaccharide compositions and use thereof in the treatment of infection
BRPI0507169A (pt) * 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
US7632924B2 (en) * 2004-06-18 2009-12-15 Ambrx, Inc. Antigen-binding polypeptides and their uses
WO2006091231A2 (en) * 2004-07-21 2006-08-31 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
US7473678B2 (en) * 2004-10-14 2009-01-06 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
CN103520735B (zh) 2004-12-22 2015-11-25 Ambrx公司 包含非天然编码的氨基酸的人生长激素配方
EP2399893B1 (en) 2004-12-22 2018-08-15 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
BRPI0519430A2 (pt) 2004-12-22 2009-02-10 Ambrx Inc hormânio do crescimento humano modificado
EP1836298B1 (en) * 2004-12-22 2012-01-18 Ambrx, Inc. COMPOSITIONS OF AMINOACYL-tRNA SYNTHETASE AND USES THEREOF
EP1836316A4 (en) 2004-12-22 2009-07-22 Ambrx Inc PROCESS FOR EXPRESSION AND CLEANING OF RECOMBINANT HUMAN GROWTH HORMONE
AU2006255122B2 (en) * 2005-06-03 2010-10-21 Ambrx, Inc. Improved human interferon molecules and their uses
JP2009501522A (ja) * 2005-07-12 2009-01-22 コドン デバイシズ インコーポレイテッド 生体触媒工学のための組成物及び方法
AU2005335491B2 (en) 2005-08-18 2010-11-25 Ambrx, Inc. Compositions of tRNA and uses thereof
FR2891149B1 (fr) 2005-09-26 2007-11-30 Biodex Sarl Composition pharmaceutique a action cicatrisante comprenant un derive de dextrane soluble et un facteur de croissance derive des plaquettes.
CN101400646A (zh) * 2005-11-08 2009-04-01 Ambrx公司 用于修饰非天然氨基酸和非天然氨基酸多肽的促进剂
DK2339014T3 (en) * 2005-11-16 2015-07-20 Ambrx Inc Methods and compositions comprising non-natural amino acids
KR20080084808A (ko) * 2005-11-17 2008-09-19 바이오미메틱 세라퓨틱스, 인크. ｒｈＰＤＧＦ-ＢＢ 및 생체적합성 매트릭스를 사용하는상악안면골 보강
WO2007070659A2 (en) * 2005-12-14 2007-06-21 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
ES2443581T3 (es) * 2006-02-09 2014-02-19 Biomimetic Therapeutics, Llc Composiciones y métodos para el tratamiento de hueso
US9161967B2 (en) 2006-06-30 2015-10-20 Biomimetic Therapeutics, Llc Compositions and methods for treating the vertebral column
AU2007269712B2 (en) 2006-06-30 2013-02-07 Biomimetic Therapeutics, Llc PDGF-biomatrix compositions and methods for treating rotator cuff injuries
EP2064333B1 (en) * 2006-09-08 2014-02-26 Ambrx, Inc. Suppressor trna transcription in vertebrate cells
CN106008699A (zh) 2006-09-08 2016-10-12 Ambrx公司 经修饰的人类血浆多肽或Fc骨架和其用途
JP5399906B2 (ja) 2006-09-08 2014-01-29 アンブルックス，インコーポレイテッド 脊椎動物細胞用のハイブリッドサプレッサーｔｒｎａ
WO2008073628A2 (en) 2006-11-03 2008-06-19 Biomimetic Therapeutics, Inc. Compositions and methods for arthrodetic procedures
US9862956B2 (en) 2006-12-10 2018-01-09 Danisco Us Inc. Expression and high-throughput screening of complex expressed DNA libraries in filamentous fungi
EP2505651A3 (en) 2006-12-10 2013-01-09 Dyadic International, Inc. Isolated fungus with reduced protease activity
CN107501407B (zh) 2007-03-30 2022-03-18 Ambrx公司 经修饰fgf-21多肽和其用途
US8114630B2 (en) 2007-05-02 2012-02-14 Ambrx, Inc. Modified interferon beta polypeptides and their uses
US8551751B2 (en) * 2007-09-07 2013-10-08 Dyadic International, Inc. BX11 enzymes having xylosidase activity
MX2010005317A (es) 2007-11-20 2010-06-02 Ambrx Inc Polipeptidos de insulina modificados y sus usos.
AU2009212151C1 (en) 2008-02-07 2015-09-17 Stryker Corporation Compositions and methods for distraction osteogenesis
MX344166B (es) 2008-02-08 2016-12-07 Ambrx Inc Leptina-polipeptidos modificados y sus usos.
CN102159230A (zh) 2008-07-23 2011-08-17 Ambrx公司 经修饰的牛g-csf多肽和其用途
BR122020000059B8 (pt) 2008-09-09 2021-06-22 Biomimetic Therapeutics Inc composição que compreende uma matriz biocompatível e um fator de crescimento derivado de plaqueta e kit
AU2009296267B2 (en) * 2008-09-26 2013-10-31 Ambrx, Inc. Non-natural amino acid replication-dependent microorganisms and vaccines
BR122012024318A2 (pt) 2008-09-26 2019-07-30 Ambrx, Inc. Polipeptídeos modificados de eritropoetina animal e seus usos
US8183346B2 (en) * 2008-12-05 2012-05-22 Eli Lilly And Company Anti-ferroportin 1 monoclonal antibodies and uses thereof
BR112012015597A2 (pt) 2009-12-21 2017-01-31 Ambrx Inc peptídeos de somatotropina suínos modificados e seus usos
MX349301B (es) 2009-12-21 2017-07-21 Ambrx Inc Polipéptidos de somatotropina bovina modificados y sus usos.
BR112012020566B1 (pt) 2010-02-22 2021-09-21 Biomimetic Therapeutics, Llc Composição de fator de crescimento derivado de plaqueta
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
EA030886B1 (ru) 2010-08-17 2018-10-31 Амбркс, Инк. Модифицированные полипептиды релаксина, содержащие некодируемую в природе аминокислоту, связанную с полимером, и их применение
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
CN105085652B (zh) * 2014-05-16 2021-06-22 中国人民解放军军事医学科学院生物工程研究所 血小板衍生生长因子b突变体、其制备方法及用途
MX2017004520A (es) 2014-10-14 2018-03-15 Lynch Samuel Composiciones para tratar heridas.
CN114805532A (zh) 2014-10-24 2022-07-29 百时美施贵宝公司 修饰的fgf-21多肽及其用途
CN106496302B (zh) * 2015-09-08 2021-12-10 三生国健药业（上海）股份有限公司 一种用离子交换层析纯化蛋白质的方法
CN108239648B (zh) * 2016-12-26 2023-04-07 丰益(上海)生物技术研发中心有限公司 高效表达米黑根毛霉脂肪酶的方法
PE20191716A1 (es) 2017-02-08 2019-12-05 Bristol Myers Squibb Co Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos
CN110590930B (zh) * 2018-06-13 2023-03-31 四川好医生攀西药业有限责任公司 美洲大蠊生长因子pdgf在制备损伤修复药物中的应用
US20210388037A1 (en) * 2018-11-19 2021-12-16 Basf Se Leader sequence for yeast

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2359180A (en) * 1942-08-11 1944-09-26 Gen Motors Corp Dynamic balancer
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
US5010003A (en) * 1983-04-25 1991-04-23 Genentech, Inc. Use of yeast homologous signals to secrete heterologous proteins
US4889919A (en) * 1986-08-13 1989-12-26 Zymogenetics, Inc. Biologically active PDGF derived A-chain homodimers
US4801542A (en) 1984-10-12 1989-01-31 Zymogenetics, Inc. Expression of biologically active PDGF analogs in eucaryotic cells
EP0487116B1 (en) * 1984-10-12 1999-12-29 ZymoGenetics, Inc. Biologically active PDGF analogs in eucaryotic cells
US5187263A (en) * 1984-10-12 1993-02-16 Zymogenetics, Inc. Expression of biologically active PDGE analogs in eucaryotic cells
US4766073A (en) * 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US4769328A (en) 1984-10-12 1988-09-06 Zymogenetics Inc. Expression of biologically active PDGF analogs in yeast
US5516896A (en) * 1985-02-25 1996-05-14 Zymogenetics, Inc. Biologically active B-chain homodimers
US5045633A (en) 1985-02-25 1991-09-03 Zymogenetics, Inc. Expression of biologically active PDGF analogs in eucaryotic cells
JPS6236183A (ja) * 1985-06-20 1987-02-17 ザ・サルク・インステイチユ−ト・バイオテクノロジ−／インダストリアル・アソシエイツ・インコ−ポレ−テツド サツカロミセス・セレビシエからのポリペプチドの発現および分泌
EP0259632B1 (en) * 1986-08-13 1995-12-13 Zymogenetics, Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US5019559A (en) 1986-11-14 1991-05-28 President And Fellows Of Harvard College Wound healing using PDGF and IGF-II
ATE88899T1 (de) 1986-11-14 1993-05-15 Inst Molecular Biology Inc Wundheilung und knochenregeneration.
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5219759A (en) * 1987-04-22 1993-06-15 Chiron Corporation Recombinant DNA encoding PDGF A-chain polypeptide and expression vectors
CA1340772C (en) * 1987-12-30 1999-09-28 Patricia Tekamp-Olson Expression and secretion of heterologous protiens in yeast employing truncated alpha-factor leader sequences
US5094941A (en) * 1987-12-31 1992-03-10 Zymogenetics, Inc. Monoclonal antibodies to PDGF
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
DK105489D0 (da) * 1989-03-03 1989-03-03 Novo Nordisk As Polypeptid
DE3900770A1 (de) * 1989-01-12 1990-07-26 Juergen Prof Dr Hoppe Verfahren zur herstellung von pdgf-a und pdgf-aa
US5968778A (en) * 1989-01-12 1999-10-19 Jurgen Hoppe PDGF-AB, preparation process and pharmaceuticals containing them
ZA911974B (en) 1990-03-21 1994-08-22 Res Dev Foundation Heterovesicular liposomes
ES2106031T3 (es) 1990-04-10 1997-11-01 Inst Molecular Biology Inc Una composicion comprendiendo un factor de crecimiento, su metodo de obtencion y uso.
US5962219A (en) * 1990-06-11 1999-10-05 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-selex
ES2055611T3 (es) * 1990-07-23 1994-08-16 Zymogenetics Inc Pdgf resistente a proteasas y metodos de uso.
ES2061416T3 (es) * 1990-10-12 1997-03-01 Max Planck Gesellschaft Ribozimas modificadas.
DK300090D0 (da) * 1990-12-19 1990-12-19 Novo Nordisk As Fremgangsmaade til fremstilling af leadersekvenser
DE4216134A1 (de) * 1991-06-20 1992-12-24 Europ Lab Molekularbiolog Synthetische katalytische oligonukleotidstrukturen
AU3062392A (en) 1991-11-04 1993-06-07 Novo Nordisk A/S Pdgf gel formulation
DE69333930T8 (de) * 1993-01-22 2007-02-22 The Regents Of The University Of Colorado, Boulder Lokalisierung von therapeutischen mitteln
PT695169E (pt) 1993-04-22 2003-04-30 Skyepharma Inc Lipossomas multivesiculares de ciclodextrina encapsulando compostos farmacologicos e metodos para a sua utilizacao
DK82893D0 (da) * 1993-07-08 1993-07-08 Novo Nordisk As Peptid
US5624803A (en) * 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
AU686277B2 (en) 1993-11-16 1998-02-05 Pacira Pharmaceuticals, Inc. Vesicles with controlled release of actives
US5902880A (en) * 1994-08-19 1999-05-11 Ribozyme Pharmaceuticals, Inc. RNA polymerase III-based expression of therapeutic RNAs
US5627053A (en) * 1994-03-29 1997-05-06 Ribozyme Pharmaceuticals, Inc. 2'deoxy-2'-alkylnucleotide containing nucleic acid
ATE386131T1 (de) * 1994-04-13 2008-03-15 Univ Rockefeller Aav-vermittelte überbringung von dna in zellen des nervensystems
US5639642A (en) * 1994-06-16 1997-06-17 Novo Nordisk A/S Synthetic leader peptide sequences
IL114160A (en) * 1994-06-17 2006-12-31 Novo Nordisk As Dna constructs encoding heterologous proteins and processes for the heterologous protein production in yeast
US6146886A (en) * 1994-08-19 2000-11-14 Ribozyme Pharmaceuticals, Inc. RNA polymerase III-based expression of therapeutic RNAs
US5716824A (en) * 1995-04-20 1998-02-10 Ribozyme Pharmaceuticals, Inc. 2'-O-alkylthioalkyl and 2-C-alkylthioalkyl-containing enzymatic nucleic acids (ribozymes)
ZA9610456B (en) * 1995-12-20 1997-06-20 Novo Nordisk As N-terminally extended proteins expressed in yeast
US5998203A (en) * 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
EP1935901A1 (en) * 1996-12-13 2008-06-25 Novartis Vaccines and Diagnostics, Inc. Analysis and separation of platelet-derived growth factor proteins
US6248878B1 (en) * 1996-12-24 2001-06-19 Ribozyme Pharmaceuticals, Inc. Nucleoside analogs
US6001311A (en) * 1997-02-05 1999-12-14 Protogene Laboratories, Inc. Apparatus for diverse chemical synthesis using two-dimensional array
US6395713B1 (en) * 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules

Also Published As

Publication number Publication date
AU5465498A (en) 1998-07-03
US7166446B2 (en) 2007-01-23
ATE398139T1 (de) 2008-07-15
DE69725881D1 (de) 2003-12-11
JP2008119008A (ja) 2008-05-29
ES2306462T3 (es) 2008-11-01
EP0946736B1 (en) 2003-10-29
JP2001518073A (ja) 2001-10-09
AU5794598A (en) 1998-07-03
JP4341859B2 (ja) 2009-10-14
PT948538E (pt) 2008-08-05
EP0948538B1 (en) 2008-06-11
JP4275741B2 (ja) 2009-06-10
EP1365028B1 (en) 2009-03-18
EP0948538A1 (en) 1999-10-13
US20060252695A1 (en) 2006-11-09
WO1998025963A1 (en) 1998-06-18
ATE253120T1 (de) 2003-11-15
JP2008031173A (ja) 2008-02-14
US7084262B2 (en) 2006-08-01
US20030036511A1 (en) 2003-02-20
US6897043B2 (en) 2005-05-24
DE69725881T2 (de) 2004-09-09
US6448382B1 (en) 2002-09-10
US6706496B2 (en) 2004-03-16
EP0946736A1 (en) 1999-10-06
US6083723A (en) 2000-07-04
EP1365028A1 (en) 2003-11-26
EP1935901A1 (en) 2008-06-25
DE69738768D1 (de) 2008-07-24
US20020055169A1 (en) 2002-05-09
ATE426030T1 (de) 2009-04-15
US6017731A (en) 2000-01-25
US20050124042A1 (en) 2005-06-09
JP2001506497A (ja) 2001-05-22
US6312923B1 (en) 2001-11-06
WO1998026080A1 (en) 1998-06-18
US20030077831A1 (en) 2003-04-24
US6083910A (en) 2000-07-04

Similar Documents

Publication Publication Date Title
DE69739319D1 (de) Verfahren zur Expression von PDGF oder IGR Proteinen in Hefe
DE69532492D1 (de) Verfahren zur Reinigung von rekombinantem menschlichem Serumalbumin
RU95115239A (ru) Аналог эритропоэтина
DE69331507D1 (de) Verfahren zur Reinigung von menschlichem, rekombinantem Serumalbumin
ES2035920T3 (es) Aerolizacion de agente proteico terapeutico.
IT1182721B (it) Procedimento di purificazione di proteine ossee
ATE187462T1 (de) Reinigung von alpha-l-proteinaseinhibitor mittels neuen chromatographischen trennungsbedingungen
DK0409472T3 (da) Knoglemorfogenetisk protein
BR1100044A (pt) Composições de eritropoietinas homogêneas
NO990560D0 (no) Kjemisk modifiserte polypeptider
DE3177260D1 (de) Fuer plasminogen-aktivator kodierende rekombinante desoxyribonukleinsaeure und verfahren zur herstellung von plasminogen-aktivator-protein daraus.
SE9603068D0 (sv) Process for purifying a protein
DE69433742D1 (de) Bmp-10 zusammensetzungen
DE3684633D1 (de) Dipeptid-derivate von fettsaeure, verfahren zu ihrer herstellung, heilmittel, das sie enthaelt und anwendung.
DE3884356D1 (de) Verfahren zur Herstellung von Fremdprotein in Hefe, Rekombinant DNS, Transformant.
NO920671L (no) Fremgangsmaate for aktivering av rekombinante proteiner
FI964174A7 (fi) Menetelmät tehokkaisen yhdistelmä-DNA-seriiniproteaasi-inhibiittoreide n tuottamiseksi ja näiden inhibiittorien käyttöjä
DE3683512D1 (de) Verfahren zur optischen isomerisierung von optisch aktiver aminosaeure und verfahren zur herstellung von optisch aktiver aminosaeure.
KR880701777A (ko) 재조합 dna 방법에 의해 제조된 인간의 췌장 분비 트립신 억제제와 그의 제조방법
FI971100L (fi) Menetelmä yhdistelmä-DNA-proteiinien, plasmidien ja modifioitujen solujen tuottamiseksi
DE59712000D1 (de) Herstellung von Carbonsäurefluoriden
DE68925918D1 (de) Methode zur Reinigung von Antithrombin-III und Antithrombin-III-Zusammensetzung enthaltend dieses Antithrombin-III
EP0676413A3 (en) Interferon alpha / beta binding protein, its production and application.
DE68910036D1 (de) Luciferase-Gen und neue rekombinante DNA sowie Verfahren zur Herstellung von Luciferase.
DE69503956D1 (de) Verfahren zur Herstellung von optisch aktiver alpha-(Hydroxyphenoxy)-alkancarbonsäure und ihren Derivaten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition